alkermes plc (ALKS:NASDAQ GS)
Richard F. Pops
Chairman of the Board and Chief Executive Officer, Alkermes plc
|Age||Total Calculated Compensation||This person is connected to 157 board members in 10 different organizations across 5 different industries.|
See Board Relationships
As of Fiscal Year 2013
Mr. Richard F. Pops has been the Chief Executive Officer of Alkermes PLC since September 11, 2009. Mr. Pops founded Genomics Collaborative, Inc. He Co-Founded Sirtris Pharmaceuticals, Inc. He served as the President of Alkermes PLC from September 11, 2009 to September 16, 2011 and previously served as its Chief Executive Officer from February 1991 to April 1, 2007. Prior to Alkermes, he was employed by PaineWebber Development Corporation as a Vice President. He has been ...
Connaught HousePhone: 353 1 772 8000
Dublin, Co. Dublin 4
Board Members Memberships*
Founder and Director
Director At Large
Chairman of the Board and Chief Executive Officer
Independent Director, Chairman of Compensation Committee and Member of Audit Committee
Former Independent Director and Chairman of Compensation Committee
Independent Director and Member of Audit Committee
|David M. Stack||Chairman, Chief Executive Officer and President|
Pacira Pharmaceuticals, Inc.
|Thomas W. D'Alonzo Esq., J.D.||Chairman, Acting Chief Executive Officer, Acting President, Member of Audit Committee, Member of Nominating/Corporate Governance Committee and Member of Compensation Committee|
Salix Pharmaceuticals Ltd.
|Arun Sawhney B.Com., P.G.D.B.M.||Chief Executive Officer, Managing Director, Executive Director, Member of Shareholders/Investors Grievance & Share Transfer Committee, Member of Quality & Integrity Committee, Member of Science Committee and Member of Corporate Social Responsibility Committee|
Ranbaxy Laboratories Ltd.
|Bruce C. Cozadd||Co-Founder, Executive Chairman and Chief Executive Officer|
Jazz Pharmaceuticals Public Limited Company
|Alessandro E. Della Chà LL.M||Chief Executive Officer and Director|
Cosmo Pharmaceuticals S.p.A.
|--||Compensation as of Fiscal Year 2013.|